Literature DB >> 29276264

Highly Probable Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome Associated With Lenalidomide.

Anusha Shanbhag1, E Ryan Pritchard1, Kshitij Chatterjee1, Drayton A Hammond1.   

Abstract

Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a life-threatening hypersensitivity reaction to medications. We report a case of a 75-year-old African American female who presented with generalized rash with desquamation and malodorous secretions. She was febrile and hypotensive, and required vasopressors for hemodynamic instability. Sepsis secondary to skin or soft tissue infection was considered initially. However, she recently was started on lenalidomide for treatment of her multiple myeloma, and her white blood cell count of 17 K/µL with 55% eosinophils along with peripheral smear showing eosinophilia suggested lenalidomide-induced rash. Lenalidomide was discontinued, and methylprednisolone was initiated. Four days after lenalidomide discontinuation, vasopressors were discontinued. Blood cultures did not exhibit any growth. The Niranjo Adverse Drug Reaction Probability Scale score of 9 suggests lenalidomide was a highly probable cause of DRESS syndrome. The temporal relation of lenalidomide administration and development of symptoms plus improvement of rash with the discontinuation of lenalidomide and reappearance on restarting lenalidomide in the follow-up clinic strengthens our suspicion of lenalidomide-induced DRESS syndrome. Cases of lenalidomide-induced DRESS syndrome are sparse; however, DRESS syndrome is fatal in approximately 10% of patients. Providers should be aware and keep a vigilant eye out for this adverse reaction with lenalidomide.

Entities:  

Keywords:  DRESS syndrome; adverse drug reactions; drug reaction with eosinophilia and systematic symptoms; lenalidomide; rash

Year:  2017        PMID: 29276264      PMCID: PMC5735696          DOI: 10.1177/0018578717717394

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  22 in total

1.  The drug hypersensitivity syndrome: what is the pathogenesis?

Authors:  J R Sullivan; N H Shear
Journal:  Arch Dermatol       Date:  2001-03

Review 2.  Treatment of severe drug eruptions.

Authors:  J C Roujeau
Journal:  J Dermatol       Date:  1999-11       Impact factor: 4.005

3.  Erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis in lenalidomide-treated patients.

Authors:  Carmen P Castaneda; Nancy A Brandenburg; Robert Bwire; Graham H Burton; Jerome B Zeldis
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

4.  Drug reaction with eosinophilia and systemic symptoms caused by lenalidomide.

Authors:  Caterina Foti; Annarita Antelmi; Antonio Mazzocca; Francesco Saverio Vella; Paolo Romita; Stefania Pugliese; Daniela Lomazzo; Piero Portincasa; Giuseppe Palasciano
Journal:  Eur J Dermatol       Date:  2012 Nov-Dec       Impact factor: 3.328

5.  Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.

Authors:  F E Davies; N Raje; T Hideshima; S Lentzsch; G Young; Y T Tai; B Lin; K Podar; D Gupta; D Chauhan; S P Treon; P G Richardson; R L Schlossman; G J Morgan; G W Muller; D I Stirling; K C Anderson
Journal:  Blood       Date:  2001-07-01       Impact factor: 22.113

6.  Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS).

Authors:  Felicidade Santiago; Margarida Gonçalo; Ricardo Vieira; Sónia Coelho; Américo Figueiredo
Journal:  Contact Dermatitis       Date:  2010-01       Impact factor: 6.600

7.  Clinicopathological features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan.

Authors:  C-C Chiou; L-C Yang; S-I Hung; Y-C Chang; T-T Kuo; H-C Ho; S Hu; H-S Hong; W-H Chung
Journal:  J Eur Acad Dermatol Venereol       Date:  2008-07-04       Impact factor: 6.166

8.  Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.

Authors:  Alessandra Ferrajoli; Bang-Ning Lee; Ellen J Schlette; Susan M O'Brien; Hui Gao; Sijin Wen; William G Wierda; Zeev Estrov; Stefan Faderl; Evan N Cohen; Changping Li; James M Reuben; Michael J Keating
Journal:  Blood       Date:  2008-03-11       Impact factor: 22.113

9.  Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects.

Authors:  K Dredge; J B Marriott; C D Macdonald; H-W Man; R Chen; G W Muller; D Stirling; A G Dalgleish
Journal:  Br J Cancer       Date:  2002-11-04       Impact factor: 7.640

10.  Successful Treatment of Antiepileptic Drug-Induced DRESS Syndrome with Pulse Methylprednisolone.

Authors:  Celebi Kocaoglu; Ceyda Cilasun; Ece Selma Solak; Gulcan S Kurtipek; Sukru Arslan
Journal:  Case Rep Pediatr       Date:  2013-04-18
View more
  4 in total

1.  Immunomodulatory drugs suppress Th1-inducing ability of dendritic cells but enhance Th2-mediated allergic responses.

Authors:  Vien Phan; Tomoki Ito; Muneo Inaba; Yoshiko Azuma; Kayoko Kibata; Noriko Inagaki-Katashiba; Akihiro Tanaka; Atsushi Satake; Shosaku Nomura
Journal:  Blood Adv       Date:  2020-08-11

Review 2.  Drug-induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms Caused by Lenalidomide: Case Report and Review of the Literature.

Authors:  Shin-Ichi Osada; Takahiko Sato
Journal:  Acta Derm Venereol       Date:  2021-05-28       Impact factor: 3.875

3.  Acute Tubulointerstitial Nephritis in Clinical Oncology: A Comprehensive Review.

Authors:  Laura Martínez-Valenzuela; Juliana Draibe; Xavier Fulladosa; Montserrat Gomà; Francisco Gómez; Paula Antón; Josep María Cruzado; Joan Torras
Journal:  Int J Mol Sci       Date:  2021-02-26       Impact factor: 5.923

4.  Development and initial validation of a modified lymphocyte transformation test (LTT) assay in patients with DRESS and AGEP.

Authors:  Chris Weir; Jamma Li; Richard Fulton; Suran L Fernando
Journal:  Allergy Asthma Clin Immunol       Date:  2022-10-09       Impact factor: 3.373

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.